Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Common Equity (2016 - 2025)

Historic Common Equity for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $327.2 million.

  • Vanda Pharmaceuticals' Common Equity fell 3924.64% to $327.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $327.2 million, marking a year-over-year decrease of 3924.64%. This contributed to the annual value of $327.2 million for FY2025, which is 3924.64% down from last year.
  • According to the latest figures from Q4 2025, Vanda Pharmaceuticals' Common Equity is $327.2 million, which was down 3924.64% from $466.0 million recorded in Q3 2025.
  • Vanda Pharmaceuticals' 5-year Common Equity high stood at $544.9 million for Q4 2023, and its period low was $327.2 million during Q4 2025.
  • For the 5-year period, Vanda Pharmaceuticals' Common Equity averaged around $506.1 million, with its median value being $513.5 million (2022).
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Common Equity soared by 1230.61% in 2021, and later crashed by 3924.64% in 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Common Equity (Quarter) stood at $504.9 million in 2021, then rose by 4.41% to $527.2 million in 2022, then increased by 3.36% to $544.9 million in 2023, then dropped by 1.17% to $538.5 million in 2024, then crashed by 39.25% to $327.2 million in 2025.
  • Its last three reported values are $327.2 million in Q4 2025, $466.0 million for Q3 2025, and $486.3 million during Q2 2025.